HRMY vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
HRMY Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin while AVDL counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, HRMY trades at 5.4x Forward P/E with 22.2% operating margin (+12.3% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, HRMY sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | HRMY | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $2.1B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 10.9x | 16.8x | Lower Multiple | HRMY |
| Forward P/E Ratio Valuation | 5.4x | 28.8x | Lower Multiple | HRMY |
| Revenue Growth (YoY) Growth | +12.3% | +54.9% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 22.2% | 2.5% | Higher Margin | HRMY |
| Net Profit Margin Profitability | 18.1% | -0.1% | Higher Margin | HRMY |
| Return on Equity (ROE) Capital Efficiency | 18.7% | -0.3% | Higher ROE | HRMY |
| 52-Week Range Position Momentum | 38% ($26โ$43) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.55ฮฒ ยท 38% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 67.1 / 100 (BUY) | 62.9 / 100 (BUY) | Higher Composite | HRMY |